These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 35378386)
1. Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin. Shibuki K; Shimada S; Aoyama T Diabetes Metab Syndr; 2022 Apr; 16(4):102474. PubMed ID: 35378386 [TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin. Shibuki K; Shimada S; Aoyama T J Diabetes Res; 2020; 2020():6321826. PubMed ID: 33224988 [TBL] [Abstract][Full Text] [Related]
3. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794 [TBL] [Abstract][Full Text] [Related]
4. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related]
5. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989 [TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Wu D; Li L; Liu C Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Ayers D; Kanters S; Goldgrub R; Hughes M; Kato R; Kragh N Curr Med Res Opin; 2017 Sep; 33(9):1653-1661. PubMed ID: 28635331 [TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis. Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Seufert J; Pegelow K; Bramlage P Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985 [TBL] [Abstract][Full Text] [Related]
13. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Lane W; Weinrib S; Rappaport J Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014 [TBL] [Abstract][Full Text] [Related]
14. Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis. Yang W; Cai X; Gao X; Chen Y; Chen L; Ji L J Diabetes Investig; 2018 Jul; 9(4):813-821. PubMed ID: 29047219 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials. De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231 [TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Brady EM; Davies MJ; Gray LJ; Saeed MA; Smith D; Hanif W; Khunti K Diabetes Obes Metab; 2014 Jun; 16(6):527-36. PubMed ID: 24373063 [TBL] [Abstract][Full Text] [Related]
17. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739 [TBL] [Abstract][Full Text] [Related]
18. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial. Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]